NeoGenomics, Inc. (NEO): Price and Financial Metrics
GET POWR RATINGS... FREE!
NEO POWR Grades
- Momentum is the dimension where NEO ranks best; there it ranks ahead of 46.52% of US stocks.
- NEO's strongest trending metric is Sentiment; it's been moving down over the last 31 weeks.
- NEO ranks lowest in Sentiment; there it ranks in the 4th percentile.
NEO Stock Summary
- Price to trailing twelve month operating cash flow for NEO is currently 500.49, higher than 99.21% of US stocks with positive operating cash flow.
- With a year-over-year growth in debt of 281.19%, Neogenomics Inc's debt growth rate surpasses 96.22% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Neogenomics Inc is reporting a growth rate of -546.69%; that's higher than only 3.46% of US stocks.
- If you're looking for stocks that are quantitatively similar to Neogenomics Inc, a group of peers worth examining would be SDGR, DRRX, ELSE, SRCL, and EEFT.
- Visit NEO's SEC page to see the company's official filings. To visit the company's web site, go to www.neogenomics.com.
NEO Valuation Summary
- NEO's price/sales ratio is 11.9; this is 230.56% higher than that of the median Healthcare stock.
- NEO's EV/EBIT ratio has moved down 228.6 over the prior 211 months.
- Over the past 211 months, NEO's price/sales ratio has gone down 9.5.
Below are key valuation metrics over time for NEO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NEO | 2019-05-14 | 7.1 | 6.7 | 371.9 | 473.4 |
| NEO | 2018-12-17 | 4.4 | 3.8 | 146.1 | 101.7 |
| NEO | 2018-05-01 | 3.1 | 4.6 | -70.5 | 435.2 |
| NEO | 2015-10-14 | 3.6 | 5.7 | -1915.5 | 454.1 |
| NEO | 2010-11-15 | 1.4 | 13.9 | -10.5 | -13.8 |
| NEO | 2005-08-19 | 10.8 | -18.4 | -10.3 | -12.0 |
NEO Growth Metrics
- The 4 year net cashflow from operations growth rate now stands at -27.39%.
- Its 2 year revenue growth rate is now at 61.04%.
- Its 4 year price growth rate is now at 271.94%.
The table below shows NEO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-03-31 | 453.951 | 10.603 | -10.964 |
| 2020-12-31 | 444.448 | 1.46 | 4.172 |
| 2020-09-30 | 425.319 | -1.166 | -4.949 |
| 2020-06-30 | 404.547 | 16.942 | -5.363 |
| 2020-03-31 | 419.283 | 10.339 | 3.452 |
| 2019-12-31 | 408.83 | 23.369 | 8.006 |
NEO Price Target
For more insight on analysts targets of NEO, see our NEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $57.27 | Average Broker Recommendation | 1.31 (Strong Buy) |
NEO Stock Price Chart Interactive Chart >
NEO Price/Volume Stats
| Current price | $47.49 | 52-week high | $61.57 |
| Prev. close | $46.19 | 52-week low | $34.18 |
| Day low | $46.06 | Volume | 558,400 |
| Day high | $47.53 | Avg. volume | 834,206 |
| 50-day MA | $43.85 | Dividend yield | N/A |
| 200-day MA | $47.28 | Market Cap | 5.60B |
NeoGenomics, Inc. (NEO) Company Bio
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.
Latest NEO News From Around the Web
Below are the latest news stories about Neogenomics Inc that investors may wish to consider to help them evaluate NEO as an investment opportunity.
Earnings Preview: NeoGenomics (NEO) Q2 Earnings Expected to DeclineNeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Bear of the Day: NeoGenomics (NEO)Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff |
7 Growth Stocks to Buy As Meme Stock Mania FadesAs the craze for meme stocks fades away, investors should consider growth investing to generate big returns. |
The Trade Desk Has More Gas in the Tank Despite Frothy ValuationI recently suggested The Trade Desk (NASDAQ:TTD) would do well in the second half of 2021. |
Inivata Acquisition Injects NeoGenomics with Growth PotentialThe premier cancer diagnostics and pharma services company NeoGenomics (NASDAQ: NEO) has been in the headlines lately. NeoGenomics serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic, and predictive testing. The company provides oncology-focused testing methodologies and platforms to help physicians to diagnose and treat cancer. Recently, the company combined its cancer-focused research and testing services with best-in-class liquid biopsy technology, through its acquisition of England-based Inivata Ltd. Inivata is a global, commercial-stage liquid biopsy platform company. Over the past year, NeoGenomics stock has increased 28%. |
NEO Price Returns
| 1-mo | 5.82% |
| 3-mo | 15.58% |
| 6-mo | -13.65% |
| 1-year | 17.78% |
| 3-year | 219.37% |
| 5-year | 482.70% |
| YTD | -11.79% |
| 2020 | 84.07% |
| 2019 | 131.96% |
| 2018 | 42.33% |
| 2017 | 3.38% |
| 2016 | 8.89% |
Continue Researching NEO
Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...